4）细分环节上，相对看好国产AI链、AI应用/端侧传媒计算机、港股互联网。11-12月业绩空窗期，以 往规律是弱化对于当季度基本面的追逐，倾向于对12月经济会议政策、以及明年产业景气度的预期进行 定价。这三个环节的优势分别在于： 科技板块今日回调，机构指出，往后看到年底，科技线可能的几个演绎线索： 1）大概率还是主线。一是因为科技（尤其AI）和指数/风偏绑定，二是除涨价外的顺周期和红利，今年 以来即使在上涨阶段也容易相对跑输科技，或者是短暂几周领跑后被科技几天爆发式追回（比如4-5月 和10月），其中顺周期的压制来自高频数据与财报，红利的压制来自指数不断超预期及因此带来的宽基 ETF抛压。这些基本面压制、和前期股价的演绎规律，会制约投资者后续非科技方向的参与意愿。 2）绝对收益的资金来源，一是前期离场比较充分的活跃资金回流，二是在11/12月底考核期之前仍有追 净值/排名诉求的机构。 3）市值风格上可能会略倾向于中小盘，因为相当一部分完成KPI的绝对收益机构、未来两个月操作不 会太激进，年内市场量能回到3万亿以上还存在一定难度，这种氛围理论上只能支持聚焦几个容量票进 行缩容炒作、而非类似6-8月这种科技板块容 ...

Core Insights - WuXi Biologics has been included in the 2025 Hang Seng Corporate Sustainability Benchmark Index, being the only pharmaceutical company recognized in this index [1][10] - The company has also been previously honored with inclusion in the HSI ESG Index and the Hang Seng ESG 50 Index, highlighting its strong ESG performance [1][10] Sustainability Recognition - The Hang Seng Corporate Sustainability Benchmark Index acknowledges publicly listed companies with outstanding ESG performance, based on an annual sustainability assessment by the Hong Kong Quality Assurance Agency (HKQAA) [2] - WuXi Biologics has received multiple accolades for its sustainability efforts, including MSCI AAA ESG Rating, EcoVadis Platinum Medal, and recognition in the Dow Jones Sustainability Indices [5] Commitment to Sustainability - WuXi Biologics integrates sustainability principles into its business model, focusing on energy and resource efficiency, governance transparency, and employee welfare [3][8] - The company is aligned with the United Nations Sustainable Development Goals and has set greenhouse gas emissions-reduction targets approved by the Science Based Targets initiative (SBTi) [4] Business Operations - WuXi Biologics operates as a global provider of biologics Green CRDMO solutions, supporting 864 integrated client projects, including 24 in commercial manufacturing as of June 30, 2025 [7] - The company employs over 12,000 skilled professionals across various countries, leveraging technology and expertise to deliver efficient and cost-effective solutions [6][7]

10月20日，港股创新药ETF（159567）收盘跌0.46%，成交额9.07亿元。 港股创新药ETF（159567）成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数 证券投资基金，基金简称为港股创新药ETF。该基金管理费率每年0.50%，托管费率每年0.10%。港股创 新药ETF（159567）业绩比较基准为国证港股通创新药指数收益率(经估值汇率调整)。 规模方面，截止10月17日，港股创新药ETF（159567）最新份额为81.34亿份，最新规模为69.68亿元。 回顾2024年12月31日，港股创新药ETF（159567）份额为3.95亿份，规模为3.78亿元。即该基金今年以 来份额增加1957.27%，规模增加1744.35%。 来源：新浪基金∞工作室 港股创新药ETF（159567）现任基金经理为马君。马君自2024年1月3日管理（或拟管理）该基金，任职 期内收益71.34%。 最新定期报告显示，港股创新药ETF（159567）重仓股包括信达生物、药明生物、百济神州、康方生 物、中国生物制药、中国生物制药、石药集团、三生制药、翰森制药、再鼎医药，持仓占比如下。 股票代码股票名 ...

于2025年10月16日，注销2318万股已回购股份。 智通财经APP讯，药明生物(02269)发布公告，于2025年10月2日-10月16日，因期权获行使而发行合计21 万股。 ...

药明生物(02269)发布公告，于2025年10月2日-10月16日，因期权获行使而发行合计21万股。 于2025年10月16日，注销2318万股已回购股份。 ...

Core Viewpoint - WuXi Biologics (02269.HK) announced the exercise of a share issuance plan for 46,000 shares on October 16, 2025 [1] Summary by Category - Company Announcement - WuXi Biologics will issue 46,000 shares as part of its share plan on October 16, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年10月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股 ...

流动性方面，截止10月16日，港股创新药ETF（159567）近20个交易日累计成交金额309.62亿元，日均 成交金额15.48亿元；今年以来，189个交易日，累计成交金额2222.19亿元，日均成交金额11.76亿元。 港股创新药ETF（159567）现任基金经理为马君。马君自2024年1月3日管理（或拟管理）该基金，任职 期内收益68.94%。 最新定期报告显示，港股创新药ETF（159567）重仓股包括信达生物、药明生物、百济神州、康方生 物、中国生物制药、中国生物制药、石药集团、三生制药、翰森制药、再鼎医药，持仓占比如下。 来源：新浪基金∞工作室 10月16日，港股创新药ETF（159567）收盘涨2.42%，成交额14.86亿元。 港股创新药ETF（159567）成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数 证券投资基金，基金简称为港股创新药ETF。该基金管理费率每年0.50%，托管费率每年0.10%。港股创 新药ETF（159567）业绩比较基准为国证港股通创新药指数收益率(经估值汇率调整)。 规模方面，截止10月15日，港股创新药ETF（159567）最新份额为82 ...

Core Points - The Hang Seng Index fell by 1.52% on October 13, closing at 25,889.48 points, while southbound funds through the Stock Connect recorded a net inflow of HKD 19.804 billion [1] - The total trading volume for the Stock Connect on October 13 was HKD 227.017 billion, with a net buy of HKD 19.804 billion [1] - Active stocks in the Shanghai Stock Connect included Alibaba-W, which had the highest trading volume at HKD 22.610 billion, followed by SMIC and Xiaomi Group with HKD 12.670 billion and HKD 9.133 billion respectively [1] - The top net buy stock was the Tracker Fund of Hong Kong, with a net inflow of HKD 5.208 billion, despite its closing price dropping by 1.56% [1] - Tencent Holdings had the highest net sell amount at HKD 3.308 billion, with a closing price decrease of 1.92% [1] Trading Activity Summary - In the Shenzhen Stock Connect, Alibaba-W led with a trading volume of HKD 9.688 billion, followed by Xiaomi Group and SMIC at HKD 6.189 billion and HKD 5.050 billion respectively [2] - The Tracker Fund of Hong Kong recorded a net buy of HKD 2.075 billion, while the highest net sell was for Innovent Biologics at HKD 0.515 billion, with a closing price drop of 4.20% [2] - The trading data for the top active stocks included significant fluctuations in net buy and sell amounts, indicating varied investor sentiment [2]

Group 1 - The Hang Seng Index fell by 1.52% on October 13, with a total southbound trading volume of HKD 227.017 billion, including HKD 123.411 billion in buying and HKD 103.606 billion in selling, resulting in a net buying amount of HKD 19.804 billion [1] - The southbound trading through Stock Connect (Shenzhen) had a total trading volume of HKD 78.738 billion, with net buying of HKD 12.206 billion, while the trading through Stock Connect (Shanghai) had a total volume of HKD 148.279 billion and net buying of HKD 7.598 billion [1] - Alibaba-W had the highest trading volume among southbound stocks, totaling HKD 32.298 billion, followed by SMIC and Xiaomi Group-W with HKD 17.721 billion and HKD 15.323 billion respectively [1] Group 2 - Among the active stocks, the top net buying stock was the Tracker Fund of Hong Kong with a net buying amount of HKD 7.282 billion, despite a closing price drop of 1.56% [2] - Xiaomi Group-W and ZTE Corporation had the longest consecutive net buying days, with 6 and 3 days respectively, and the highest net buying amounts of HKD 4.709 billion and HKD 1.673 billion [2] - The stocks with the highest net selling amounts included Tencent Holdings with HKD 2.445 billion, Alibaba-W with HKD 1.624 billion, and SMIC with HKD 0.524 billion [2]